Zoono Group Limited · ASX:ZNO
Zoono — H1 FY22 Earnings Presentation
10 slides from Zoono's earnings presentation, Feb 24, 2022
Slide 1: ASX lodgement approval notice
This presentation has been approved for lodgement with ASX by the Board of Zoono Group Limited.
Slide 2: Zoono Group Limited Financial Report
ZOONO GROUP LIMITED FINANCIAL REPORT GROUP CHIEF FINANCIAL OFFICER ZOONO’
Slide 3: Group Financial Highlights
GROUP FINANCIAL HIGHLIGHTS (Poor Result H1 FY22) 31 December 2021 31 December 2020 31 December 2021 31 December 2020 (NZD) (NZD) Q 3 2 3 a g 2 8 $ = EBITDA: : : 8 cents per share (Loss)/Profit before tax: 7 ; are (Loss)/Profit after tax: iM. Cash at bank: Total Assets: Total Equity: NB: PLEASE REFER
Slide 4: Balance Sheet Summary
BALANCE SHEET SUMMARY 31 December 2021 31 December 2020 (NZD) (NZD) $10.3M $10.6M (includes Deferred Income of $0.1M) | (includes Deferred Income of $0.3M) ’ $19.1M $21.1M Total Equity (65% of Total Assets) (66% of Total Assets) NB: PLEASE REFER TO 31 December 2021 HALF-YEAR REPORT FOR FURTHER DETAI
Slide 5: Summary Performance
SUMMARY PERFORMANCE IS all on Financial performance down, Still high Gross Margins Good cash generation despite despite cash at bank up compared to corresponding softer sales period Slightly higher overheads despite $1.7M of legal costs Low capital investment model Zoono Group Limited Half -Year Res
Slide 6: FY22 Priorities
FY22 PRIORITIES PAUL HYSLOP CEO ZOONO’ a
Slide 7: FY22 Priorities
FY22 PRIORITIES Continue to transition and stabilise from the COVID in environment into delivering ongoing, long-term ani growth by: ¥ Prioritisation of opportunities offering the greatest pote term value creation. v Growing existing key customers and revenue streams i geographical and vertical mark
Slide 8: Driving revenue growth is the key focus across the Company
Driving revenue growth is and will continue to be the key focus across the Company. To that end, the Company notes the following positive developments ✓ ✓ ✓ ✓ ✓
Slide 9: Important Notice & Disclaimer
Important Notice & Disclaimer Commercial in Confidence Zoono has not audited or investigated the accuracy or completeness of the information, statements and opinions contained in this presentation. Whilst provided in good faith, to the maximum extent permitted by applicable laws, Zoono makes no repr
Slide 10: Zoono - Questions?
ZOONO The next generation of antibacterial technology Questions? Zoono Group Limited Half —Year Results Presentation - December 31 2021 ZOO NO